Table 4.
Correlation between GSIS and biomarkers (n = 63)
| GSIS | p value | ||
|---|---|---|---|
| Immune‐hot | Immune‐cold | ||
| DRD status | |||
| Wild type | 16 | 23 | .03 |
| Mutation | 11 | 3 | |
| N/A | 3 | 7 | |
| BRCA status | |||
| Wild type | 19 | 23 | .18 |
| Mutation | 8 | 3 | |
| N/A | 3 | 7 | |
| Stromal TIL level | |||
| Low (0%–10%) | 8 | 25 | <.001 |
| Medium (11%–59%) | 16 | 6 | |
| High (≥60%) | 5 | 1 | |
| N/A | 1 | 1 | |
| TNBC molecular subtype | |||
| BL1 | 5 | 6 | <.001 |
| BL2 | 2 | 3 | |
| IM | 16 | 0 | |
| LAR | 1 | 6 | |
| M | 0 | 15 | |
| MSL | 1 | 3 | |
| UNS | 5 | 0 | |
| pCR | |||
| Yes | 20 | 10 | .005 |
| No a | 10 | 23 | |
| RCB class | |||
| 0/I | 24 | 15 | .009 |
| II/III a | 6 | 18 | |
| BluePrint | |||
| Luminal | 0 | 2 | .49 |
| Basal | 30 | 31 | |
| MammaPrint | |||
| H1 | 3 | 8 | .19 |
| H2 | 27 | 25 | |
a
One immune‐cold patient progressed prior to surgery and was included in the non‐pCR RCB II/III group for analysis purposes.
Abbreviations: BL1, basal‐like 1; BL2, basal‐like 2; DRD, DNA repair defect; GSIS, GeparSixto immune signature; IM, immunomodulatory; LAR, luminal androgen receptor; M, mesenchymal; MSL, mesenchymal stem‐like; N/A, not applicable; pCR, pathological complete response; RCB, residual cancer burden; TIL, tumor‐infiltrating lymphocyte; TNBC, triple‐negative breast cancer; UNS, unspecified.